Bryant Ranch Prepack Initiates Class III Recall of Cephalexin Oral Suspension Due to Labeling Error
Bryant Ranch Prepack, Inc. has initiated a Class III recall (D-0539-2024) for 190 bottles of Cephalexin for Oral Suspension, USP, due to a minor labeling discrepancy. This voluntary action, impacting nationwide distribution, underscores the critical need for meticulous quality control in pharmaceutical relabeling operations and highlights potential supply chain vulnerabilities for procurement and regulatory teams.
FDA Oversees Class III Recall of Bryant Ranch Prepack's Cephalexin Oral Suspension
The U.S. Food and Drug Administration (FDA) is overseeing a Class III voluntary recall, identified as D-0539-2024, initiated by Bryant Ranch Prepack, Inc. of Burbank, CA. This action concerns 190 bottles of Cephalexin for Oral Suspension, USP, 250mg per 5mL, an essential oral antibiotic. The recall, which began on May 10, 2024, stems from a labeling error on the product's back label. Specifically, the label incorrectly states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of the accurate phrasing, 'Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g'. While classified as Class III, indicating that exposure is not likely to cause adverse health consequences, this event highlights the critical importance of absolute precision in pharmaceutical labeling. For procurement directors and regulatory affairs heads, this means that even seemingly minor textual discrepancies can trigger nationwide recalls, disrupting supply chains and necessitating costly remediation efforts. Ensuring stringent quality checks at every stage of the packaging and relabeling process is paramount to avoid such compliance breaches and maintain product availability across the United States.
Operational Implications for Bryant Ranch Prepack's Relabeling Operations in Burbank, CA
Bryant Ranch Prepack, Inc., operating from its Burbank, CA facility at 1919 N Victory Pl, functions as a relabeler for pharmaceutical products, including the Cephalexin for Oral Suspension manufactured by Alkem Laboratories Ltd. The current recall directly implicates Bryant Ranch Prepack's internal quality control and labeling processes. The error, involving a missing word on the back label, suggests a lapse in final artwork verification or quality assurance checks prior to distribution. For supply chain VPs, this incident underscores the necessity of rigorous vendor qualification and continuous oversight for all third-party relabeling and packaging partners. A relabeling error, even if minor, can lead to significant logistical challenges, including the identification, segregation, and return of affected lots (Lot: 235288, 235294, 235368, 235806, 236058, 236138, 236139, 236351, 236490, 236757, 236877, 236758, 236762, 237254, 237349, 237401, 237807). Business development executives must consider the reputational impact of such recalls, even if Class III, as they can signal underlying weaknesses in a partner's quality management system, affecting future contracting opportunities.
Supply Chain Exposure and Distribution Footprint for Recalled Cephalexin Lots
The recalled Cephalexin for Oral Suspension was distributed nationwide in the USA, affecting 190 bottles across 17 distinct lots with expiration dates ranging from November 30, 2025, to December 31, 2025. While the quantity is relatively small, the nationwide distribution pattern means that numerous pharmacies, distributors, and potentially patients could be impacted. For procurement directors, this event highlights the importance of granular traceability within the supply chain. Understanding precisely where each lot of a critical antibiotic like Cephalexin has been distributed is essential for efficient and effective recall execution. Regulatory affairs heads must ensure that their recall procedures are robust enough to handle such widespread, albeit low-severity, events, minimizing disruption while maintaining compliance with FDA requirements. The need for clear communication and rapid action across the distribution network is paramount, even for a Class III classification, to safeguard public trust and operational continuity.
Strategic Procurement Considerations for Oral Antibiotic Sourcing
This recall, while specific to a labeling error by Bryant Ranch Prepack, serves as a reminder for procurement teams regarding the broader landscape of oral antibiotic sourcing. Cephalexin (UNII: OBN7UDS42Y) is a widely used antibiotic, and ensuring its consistent supply requires a diversified and resilient procurement strategy. Given the absence of specific alternative suppliers in the available intelligence for Bryant Ranch Prepack's relabeling services, procurement directors should proactively identify and qualify multiple relabeling and packaging partners, beyond primary manufacturers like Alkem Laboratories Ltd. This diversification mitigates risks associated with quality control lapses at any single vendor. Furthermore, establishing stringent quality agreements that clearly define labeling specifications, audit rights, and recall responsibilities is crucial. Business development executives should evaluate potential partners not only on cost but also on their demonstrated commitment to quality and regulatory compliance, ensuring that all aspects of the supply chain, including relabeling, meet the highest industry standards.
Broader Regulatory Landscape and Compliance Vigilance in Pharmaceuticals
The FDA's oversight extends across the entire pharmaceutical supply chain, as evidenced by this Class III recall for Cephalexin. While a labeling error is less severe than issues like particulate matter or temperature excursions, it underscores the agency's continuous vigilance. Recent parallel events highlight the diverse range of regulatory challenges faced by the industry: Pfizer faced Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter, indicating severe manufacturing quality issues. Sandoz experienced a Class II recall for Enoxaparin Sodium due to CGMP temperature excursion risks, impacting product integrity. Similarly, Teva Pharmaceuticals' Warfarin Sodium and Allergan's ARMOUR THYROID were subject to Class II recalls linked to Cardinal Healthcare's storage deviations. For regulatory affairs heads, these varied incidents, from manufacturing defects to storage and labeling errors, emphasize the need for a holistic compliance strategy. Proactive monitoring of FDA actions, understanding the nuances between Class I, II, and III recalls, and implementing robust quality management systems across all operational touchpoints are essential to navigate this complex regulatory environment and protect market access.